MORPHIC HOLDING INC (MORF) Stock Price, Quote, News and Overview
NASDAQ:MORF - Nasdaq - US61775R1059 - Common Stock - Currency: USD
MORF Quote, Performance and Key Statistics
56.99
+0.02 (+0.04%)
The current stock price of MORF is 56.99 USD. In the past month the price increased by 1.19%. In the past year, price increased by 5.11%.
MORF Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.96 | 321.60B | ||
| AMGN | AMGEN INC | 14.08 | 150.09B | ||
| GILD | GILEAD SCIENCES INC | 13.29 | 128.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1689.86 | 125.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 13 | 64.86B | ||
| ARGX | ARGENX SE - ADR | 325.8 | 37.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.19B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.75B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 25.34B | ||
| NTRA | NATERA INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B |
Related stock screener links
About MORF
Company Profile
Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2019-06-27. The firm is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The firm is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). The company has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.
Company Info
MORPHIC HOLDING INC
35 Gatehouse Drive A2
Waltham MASSACHUSETTS 02451 US
CEO: Praveen P. Tipirneni
Employees: 124
Company Website: https://morphictx.com/
Phone: 17819960955
MORPHIC HOLDING INC / MORF FAQ
What is the stock price of MORPHIC HOLDING INC today?
The current stock price of MORF is 56.99 USD. The price increased by 0.04% in the last trading session.
What is the ticker symbol for MORPHIC HOLDING INC stock?
The exchange symbol of MORPHIC HOLDING INC is MORF and it is listed on the Nasdaq exchange.
On which exchange is MORF stock listed?
MORF stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MORPHIC HOLDING INC stock?
15 analysts have analysed MORF and the average price target is 59.6 USD. This implies a price increase of 4.57% is expected in the next year compared to the current price of 56.99. Check the MORPHIC HOLDING INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MORPHIC HOLDING INC worth?
MORPHIC HOLDING INC (MORF) has a market capitalization of 2.85B USD. This makes MORF a Mid Cap stock.
How many employees does MORPHIC HOLDING INC have?
MORPHIC HOLDING INC (MORF) currently has 124 employees.
What are the support and resistance levels for MORPHIC HOLDING INC (MORF) stock?
MORPHIC HOLDING INC (MORF) has a support level at 56.98 and a resistance level at 57. Check the full technical report for a detailed analysis of MORF support and resistance levels.
Is MORPHIC HOLDING INC (MORF) expected to grow?
The Revenue of MORPHIC HOLDING INC (MORF) is expected to decline by -50.42% in the next year. Check the estimates tab for more information on the MORF EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MORPHIC HOLDING INC (MORF) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MORF, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MORF, evaluating the profitability, health, valuation and growth aspects
- MORPHIC HOLDING INC (MORF) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MORPHIC HOLDING INC (MORF) Sales and EPS estimates to see what analysts future expectations are.
- MORPHIC HOLDING INC (MORF) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MORPHIC HOLDING INC (MORF) Insider and Institutional Ownership to learn about the owners and their transactions.
- MORPHIC HOLDING INC (MORF) Stock Chart to make your own analysis
- MORPHIC HOLDING INC (MORF) Latest news and press-releases to stay up to date.
Does MORPHIC HOLDING INC (MORF) stock pay dividends?
MORF does not pay a dividend.
When does MORPHIC HOLDING INC (MORF) report earnings?
MORPHIC HOLDING INC (MORF) will report earnings on 2024-11-01, before the market open.
What is the Price/Earnings (PE) ratio of MORPHIC HOLDING INC (MORF)?
MORPHIC HOLDING INC (MORF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.75).
MORF Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MORF. When comparing the yearly performance of all stocks, MORF is one of the better performing stocks in the market, outperforming 94.75% of all stocks.
MORF Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MORF. While MORF has a great health rating, there are worries on its profitability.
MORF Financial Highlights
Over the last trailing twelve months MORF reported a non-GAAP Earnings per Share(EPS) of -3.75. The EPS decreased by -15.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.83% | ||
| ROE | -29.08% | ||
| Debt/Equity | 0 |
MORF Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to MORF. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -16.05% and a revenue growth -50.42% for MORF